June 2010
Prepared for: Advamed
Lewin Contact: Cliff Goodman
This report presents updated estimates of the medical technology industry’s (MTI) economic contributions from the previous industry analysis, which was released in 2007. The industry encompasses the manufacturing of everyday medical devices, such as contact lenses and thermometers, to high-tech equipment, such as implantable pacemakers, neurostimulators and state-of-the-art imaging systems. Each of the 50 States and the District of Columbia are benefitted by MTI establishments; nearly all have seen this industry grow since the 2007 report.
Client Area: Associations, Pharma / Bio / Device
April 2009
Novo Nordisk
For Novo Nordisk, The Lewin Group estimated the economic costs of diagnosed type 1 (T1DM) and type 2 (T2DM) diabetes mellitus in the United States in 2007. Lewin analyzed medical claims to estimate the proportion of diagnosed diabetes cases and excess medical costs by diabetes type. Indirect costs associated with T1DM and T2DM were estimated by using findings from the literature on diagnosed diabetes, as well as differences in health per case of T1DM and T2DM. This study builds on the Cost of Diabetes Model developed by Lewin for the American Diabetes Association to estimate the economic burden of diagnosed diabetes. The study is published in the journal Population Health Management.
Client Area: Pharma / Bio / Device
Expertise Area: Chronic Disease / Cost of Illness
April 2009
Novo Nordisk
For Novo Nordisk, The Lewin Group conducted a study to estimate the national economic costs associated with undiagnosed diabetes mellitus (UDM). This study builds on previous work on the national costs associated with diagnosed diabetes mellitus. Lewin used a Cost of Diabetes Model that combines data from multiple sources to estimate the national prevalence of UDM in 2007; to quantify differences in health care use patterns for a proxy for the population with UDM compared to a population with no history of diabetes; to estimate the proportion of national health care use and expenditures associated with UDM; and to estimate the loss in national productivity. The study is published in the journal Population Health Management.
Client Area: Pharma / Bio / Device
Expertise Area: Chronic Disease / Cost of Illness
January 2009
Olympus America, Inc.
The purpose of this study is to assess the future adequacy of gastroenterologist supply to help ensure the nation’s ability to provide colonoscopy services. Using two simulation models—the National Colorectal Screening Model and the Physician Supply and Demand Model—the report authors provide evidence-based extrapolations of the impact of changes in CRC screening rates, trends in screening modality, and other trends in gastroenterologist supply and demand determinants on the future adequacy of gastroenterologist supply.
Client Area: Pharma / Bio / Device
Expertise Area: Chronic Disease / Cost of Illness
January 2004
Wyeth Consumer Healthcare
The Lewin Group was commissioned by Wyeth Consumer Healthcare to develop estimates of the economic impact of the use of daily multivitamins by older adults within a health insurance context (e.g., Medicare or some other payer). The study found that daily use of a multivitamin by older adults is a relatively inexpensive yet potentially powerful way to improve one's health. The study found that the health effects were particularly important for cardiovascular health and improved immune functioning. From the perspective of a payer, the encouragement of the daily use of a multivitamin could be cost beneficial.
Client Area: Pharma / Bio / Device
Showing 1 to 5 of 5 item(s)